World's Best Scientists 2026 revealed!
Nikolai V. Naoumov

Nikolai V. Naoumov

D-Index & Metrics

Microbiology

D-Index
64
Citations
16073
World Ranking
2596
National Ranking
63

Overview

Nikolai V. Naoumov is affiliated with Novartis in Switzerland. The primary area of their research is within medicine, with a specific focus on epidemiology and hepatology. Their contributions also span pathology and forensic medicine, as well as studies related to animal science, zoology, endocrinology, diabetes, and metabolism.

The scientist's work primarily addresses various aspects of liver disease, including diagnosis and treatment, immunity related to liver diseases, transplantation, and prognosis. Studies also cover hepatocellular carcinoma treatment and hepatitis B virus investigations. Research on the effects of alcohol consumption on health and animal virus infections form part of their broader academic inquiry.

Nikolai V. Naoumov has co-authored publications with notable frequent collaborators, including Elaine Chng, Dean Tai, Arun J. Sanyal, Yayun Ren, and Dominique Brees.

Their scholarship has been published in several prominent journals, with multiple articles appearing in the Journal of Hepatology. Other venues include Nature Medicine, Hepatology, Clinical Gastroenterology and Hepatology, and Gut.

Recent publications by or involving Nikolai V. Naoumov include:

  • Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH, 2022, Journal of Hepatology
  • IL-1 Signal Inhibition in Alcohol-Related Hepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial of Canakinumab, 2024, Clinical Gastroenterology and Hepatology

Other relevant papers, though authored primarily by collaborators but reflective of the research environment, include:

  • Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial, 2023, Nature Medicine
  • Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study, 2023, Hepatology
  • High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy, 2024, Gut

Best Publications

  • Telbivudine versus lamivudine in patients with chronic hepatitis B.

    Ching-Lung Lai;Edward Gane;Yun-Fan Liaw;Chao-Wei Hsu

  • The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection.

    Mala K. Maini;Carolina Boni;Chun Kyon Lee;Juan R. Larrubia

  • Long-Term Outcome of Hepatitis C Infection after Liver Transplantation

    Edward J. Gane;Bernard C. Portmann;Nikolai V. Naoumov;Heather M. Smith

  • 2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B

    Yun–Fan Liaw;Edward Gane;Nancy Leung;Stefan Zeuzem

  • A longitudinal analysis of hepatitis C virus replication following liver transplantation

    E. J. Gane;N. V. Naoumov;K.-P. Qian;M. U. Mondelli

  • Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

    Emmet B. Keeffe;Stefan Zeuzem;Raymond S. Koff;Douglas T. Dieterich

  • Hepatitis C virus–specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C

    Matthew E. Cramp;Siegbert Rossol;Shilpa Chokshi;Shilpa Chokshi;Patrizia Carucci

  • Presence of a newly described human DNA virus (TTV) in patients with liver disease

    Nikolai V Naoumov;Elena P Petrova;Mark G Thomas;Roger Williams

  • Hepatitis C Virus Persistence after Spontaneous or Treatment-Induced Resolution of Hepatitis C

    Tram N. Q. Pham;Sonya A. MacParland;Patricia M. Mulrooney;Helen Cooksley

  • Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China.

    G. Zeng;Z. Wang;S. Wen;J. Jiang

  • Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen–positive patients

    Karsten Wursthorn;Mechthild Jung;Antonio Riva;Zachary D. Goodman

  • Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B

    Stefan Zeuzem;Edward Gane;Yun Fan Liaw;Seng G. Lim

  • CD8+ T Cell Control of Hepatitis B Virus Replication: Direct Comparison between Cytolytic and Noncytolytic Functions

    Sandra Phillips;Shilpa Chokshi;Antonio Riva;Alexander Evans

  • Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e‐antigen seroconversion

    Alexander Evans;Antonio Riva;Helen Cooksley;Sandra Phillips

  • Shared Alterations in NK Cell Frequency, Phenotype, and Function in Chronic Human Immunodeficiency Virus and Hepatitis C Virus Infections

    Ute-Christiane Meier;Rachel E. Owen;Elizabeth Taylor;Andrew Worth

  • Precore mutant hepatitis B virus infection and liver disease

    Nikolai V. Naoumov;Ralf Schneider;Thilo Grötzinger;Maria C. Jung

  • Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen.

    George K.K. Lau;Deepak Suri;Raymond Liang;Eirini I. Rigopoulou

  • Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia

    Matthew E. Cramp;Patrizia Carucci;James Underhill;Nikolai V. Naoumov

  • A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation.

    Edward J. Gane;Su-Kong Lo;Stephen M. Riordan;Stephen M. Riordan;Bernard C. Portmann

  • Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia

    M E Cramp;P Carucci;S Rossol;S Chokshi

  • The role of virus-specific CD8+cells in liver damage and viral control during persistent hepatitis B virus infection

    M K Maini;C Boni;K Lee;Larrubia

Frequent Co-Authors

Roger Williams
Roger Williams Foundation for Liver Research
Jinlin Hou
Jinlin Hou Southern Medical University
Ching-Lung Lai
Ching-Lung Lai University of Hong Kong
Bernard Portmann
Bernard Portmann King's College London
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Graeme J. M. Alexander
Graeme J. M. Alexander University College London
George K. K. Lau
George K. K. Lau Humanity & Health
Geert Maertens
Geert Maertens Biocartis (Belgium)
Stephen Locarnini
Stephen Locarnini Melbourne Health
Mark G. Thomas
Mark G. Thomas University College London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in microbiology, exploring related online degrees can open diverse career opportunities in healthcare and science. One practical option is pursuing an online medical billing and coding certificate fast. This certification provides a quick pathway into administrative roles within medical facilities, complementing a science background.

Additionally, many learners consider broader healthcare fields. There are numerous online healthcare degrees available that offer flexibility and specialization options, such as public health or health informatics, which align well with microbiology knowledge.

If you’re looking to advance quickly in public health, exploring online MPH programs easy to get into can be an excellent choice. These programs often provide accessible entry points and can enhance career prospects in epidemiology and disease control.

Career pathways related to microbiology also include roles focused on patient care and support, such as child life specialists. Understanding how much do child life specialists make and the steps to enter this field can guide microbiology graduates interested in holistic healthcare roles.

Best Scientists Citing Nikolai V. Naoumov

Trending Scientists